Actively Recruiting
Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
Led by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Updated on 2025-09-24
350
Participants Needed
7
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
CONDITIONS
Official Title
Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Diagnosed with migraine with or without high-frequency episodic aura (more than 8 days of migraine per month) or chronic migraine by a headache expert using International Classification of Headache Diseases, 3rd edition criteria.
- History of migraine for at least one year.
- Stable preventive treatment for at least one month before starting monoclonal antibody treatment and no botulinum toxin in the month prior.
- Able to describe their clinical situation and headache characteristics.
- Provide informed consent.
You will not qualify if you...
- Any other type of headache besides migraine, except for headache caused by overuse of pain medication.
- Presence of neurological abnormalities on examination.
- Pregnancy or breastfeeding.
- Cognitive impairment or conditions that prevent proper study participation.
- Need for changes in preventive treatment during the first 6 months after starting monoclonal antibody treatment.
- Significant adverse effects requiring stopping or changing anti-CGRP treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Aragon, Spain, 50009
Actively Recruiting
2
Hospital Universitario Donostia
Donostia / San Sebastian, Basque Country, Spain, 20014
Actively Recruiting
3
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain, 39008
Actively Recruiting
4
Hospital Clínico Universitario de Valladolid
Valladolid, Castille and León, Spain, 47010
Actively Recruiting
5
Hospital Universitari Vall d'Hebron Research Institute
Barcelona, Catalonia, Spain, 08035
Actively Recruiting
6
Hospital Universitario de La Princesa
Madrid, Madrid, Spain, 28006
Actively Recruiting
7
Hospital Universitario Politécnico La Fe
Valencia, Valencia, Spain, 46026
Actively Recruiting
Research Team
A
Ana Beatriz Gago Veiga
CONTACT
I
Iris Fernández Lázaro
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here